- Home
- GRDN vs DYN Comparison
GRDN vs DYN Comparison
Compare GRDN & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRDN
- DYN
- Stock Information
- Founded
- GRDN 2004
- DYN 1984
- Country
- GRDN United States
- DYN United States
- Employees
- GRDN N/A
- DYN N/A
- Industry
- GRDN Retail-Drug Stores and Proprietary Stores
- DYN Medicinal Chemicals and Botanical Products
- Sector
- GRDN Consumer Staples
- DYN Health Care
- Exchange
- GRDN Nasdaq
- DYN Nasdaq
- Market Cap
- GRDN 1.7B
- DYN 1.9B
- IPO Year
- GRDN 2024
- DYN 2020
- Fundamental
- Price
- GRDN $24.90
- DYN $16.41
- Analyst Decision
- GRDN Strong Buy
- DYN Strong Buy
- Analyst Count
- GRDN 3
- DYN 14
- Target Price
- GRDN $27.00
- DYN $34.93
- AVG Volume (30 Days)
- GRDN 287.0K
- DYN 2.4M
- Earning Date
- GRDN 11-10-2025
- DYN 11-11-2025
- Dividend Yield
- GRDN N/A
- DYN N/A
- EPS Growth
- GRDN N/A
- DYN N/A
- EPS
- GRDN N/A
- DYN N/A
- Revenue
- GRDN $1,326,604,000.00
- DYN N/A
- Revenue This Year
- GRDN $16.17
- DYN N/A
- Revenue Next Year
- GRDN $2.31
- DYN N/A
- P/E Ratio
- GRDN N/A
- DYN N/A
- Revenue Growth
- GRDN 18.53
- DYN N/A
- 52 Week Low
- GRDN $16.91
- DYN $6.36
- 52 Week High
- GRDN $30.39
- DYN $35.77
- Technical
- Relative Strength Index (RSI)
- GRDN 50.11
- DYN 70.34
- Support Level
- GRDN $23.37
- DYN $13.73
- Resistance Level
- GRDN $24.86
- DYN $17.00
- Average True Range (ATR)
- GRDN 0.96
- DYN 0.77
- MACD
- GRDN -0.03
- DYN 0.33
- Stochastic Oscillator
- GRDN 48.58
- DYN 87.55
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.